Immunomodulators in the treatment of cutaneous lymphomas

Bibliography

• KAYE FJ, BUNN PJ, STEINBERG SM et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl. J Med. (1989) 321:1784–1790.
   PubMed Web of Science ®Google Scholar
• ••Large randomised trial comparingaggressive versus non-aggressive therapy in CTCL.
   Google Scholar
• BURG G, DUMMER R, KERL H: Classification of cutaneous lymphomas. Berm. Clinics (1993) 12:213–217.
   Web of Science ®Google Scholar
• DUMMER R, WILLERS J, KAMARASHEV J, UROSEVIC M, DOBBELING U, BURG G: Pathogenesis of cutaneous lymphomas. Semin. Cutari. Med. Surg. (2000) 19:78–86.
   PubMed Web of Science ®Google Scholar
• DUMMER R, HEALD PW, NESTLE FO et al: Sezary Syndrome's T-cell clones display T helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta chain). Blood (1996) 88:1383–1389.
   PubMed Web of Science ®Google Scholar
• •Functional characterisation of clonal T-cells in SS.
   Google Scholar
• ASADULLAH K, DOCKE, W-D, HAEUSSLER A, STERRY W, VOLK H-D: Progression of Mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 (IL-10) mRNA. Invest. Dermatal. (1996) 107:833–837.
   PubMed Web of Science ®Google Scholar
• SAUDER DN: Immunomodulatory and pharmacologic properties of imiquimod. Am. Acad. Dermatal. (2000) 43:S6–S11.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, WANG B, SHIVJI GM etal.: Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. j Invest. Dermatal. (2000) 114:135–141.
   Google Scholar
• •Information on the mode of action of imiquimod.
   Google Scholar
• DUMMER R, WELTERS H, KEILHOLZ U, TILGEN W, BURG G: Interleukin 2: immunologischer Hintergrund und klinische Anwendung in der Tumortherapie. Hautarzt (1990) 41:53–55.
   PubMedGoogle Scholar
• GISSELBRECHT C, MARANINCHI D, PICO JL et al: Interleukin-2 treatment in lymphoma: a Phase II multicenter study. Blood (1993) 83:2081–2085.
   Web of Science ®Google Scholar
• BRUNDA MJ: Interleukin-12. _J. Leukocyte Biol. (1993) 55:280–288.
   Google Scholar
• ROOK AH, WOOD GS, Y00 EK et aL: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood (1999) 94:902–908.
   PubMed Web of Science ®Google Scholar
• ••Important study on rationalimmunotherapy in CTCL.
   Google Scholar
• SIMONI D, MANFREDINI S, TABRIZI MA et al.: New isoxazole derivatives of retinoids: synthesis and activity on growth and differentiation of tumor cells. Drug Des. Discov. (1992) 8:165–177.
   PubMedGoogle Scholar
• STADLER R, OTTE HG, LUGER T etal.: Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood (1998) 92:3578–3581.
   Google Scholar
• ••Prospective randomised trial comparingtwo standard therapies.
   Google Scholar
• SHERMAN SI, GOPAL J, HAUGEN BR et al.: Bexarotene (Targretin) for cutaneous T-cell lymphoma: Central hypothyroidism associated with retinoid X receptor-selective ligands. Med. Lett. Drugs Ther. (2000) 42:31–32.
   PubMedGoogle Scholar
• FOSS FM, BORKOWSKI TA, GILLIOM M et al.: Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a Phase II study. Blood (1993) 84: 1765-1774.
   Google Scholar
• SALEH MN, LEMAISTRE CF, KUZEL TM et al.: Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. j Am. Acad. Dermatal. (1998) 39:63–73.
   PubMed Web of Science ®Google Scholar
• FOSS FM, RAUBITSCHECK A, MULSHINE JL et al.: Phase I study of the Pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Chu. Cancer Res. (1998) 4:2691–2700.
   PubMed Web of Science ®Google Scholar
• ROGALSKI C, DUMMER R, BURG G: Immunomodulators in the treatment of cutaneous lymphoma. j Eur. Acad. Dermatal. Venereal (1999) 113:83–90.
   Google Scholar
• VOWELS BR, CASSIN M, BOUFAL MH, WALSH LJ, ROOK AH: Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. j Invest. Dermatal. (1992) 98:686–692.
   PubMed Web of Science ®Google Scholar
• DUMMER R, LAINE E, DOBBELING U, BURG G, NESTLE F:T-cell relevant cytokines during extracorporeal photopheresis (ECP) in Sezary syndrome, detected by a newly developed PCR-ELISA technique. I Invest. Dermatal. (1995) 104:653. Abstract.
   Google Scholar
• VONDERHEID EC, BIGLER RD, GREENBERG AS, NEUKUM SJ, MICAILY B: Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response. Am j Clin. Oricol (1993) 17:255–263.
   Google Scholar
• FRITZ T, KLEINHANS M, NESTLE F, BURG G, DUMMER R: Combination treatment with extracorporeal photopheresis, Interferon alfa and interleukin-2 in a patient with the Sézary syndrome. Br. j Dermatol. (1999) 140:1144–1147.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328–332.
   PubMed Web of Science ®Google Scholar
• LINNEMANN T, WIESMULLER KH, GELLRICH S, KALTOFT K, STERRY W, WALDEN P: A T-cell epitope determined with random peptide libraries and combinatorial peptide chemistry stimulates T cells specific for cutaneous T-cell lymphoma. Ann. Oricol (2000) 11\(Suppl. 1)95–99.
   Google Scholar
• EICHMUELLER S, USENER D, DUMMER R, STEIN A, THIEL D, SCHADENDORF D: Serological detection of cutaneous T-cell lymphoma-associated antigens. PNAS (2001) 98:629–634.
   PubMed Web of Science ®Google Scholar
• DUMMER R, NESTLE FO: Melanoma vaccines in development: looking to the future. Biodrugs (2000) 13:227–231.
   PubMed Web of Science ®Google Scholar
• KUPPERS R, KLEIN U, HANSMANN M-L, RAJEWSKY K: Cellular origin of human B-cell lymphomas. N Engl. j Med. (1999) 11:1520–1529.
   Google Scholar
• ••Excellent overview of the immunobiologyof B-cell lymphomas.
   Google Scholar
• CERRONI L, ZOCHLING N, PUTZ B, KERL H: Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. j Cutan. Pathol (1997) 24:457–461.
   PubMed Web of Science ®Google Scholar
• HOFBAUER GFL, KESSLER B, KEMPF W, NESTLE FO, BURG G, DUMMER R: Multilesional primary cutaneous diffuse large cell B-cell lymphoma responsive to antibiotic treatment. Dermatology (2001) 203:168–170.
   PubMed Web of Science ®Google Scholar
• DAVIS TA, GRILLO LOPEZ AJ, WHITE CA et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. j Clin. Oricol (2000) 18:3135–3143.
   PubMed Web of Science ®Google Scholar
• GOLAY J, ZAFFARONI L, VACCARI T etal.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95:3900–3908.
   Google Scholar
• HARJUNPA AA, JUNNIKKALA, S, MERI, S: Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Stand. j Immurrol (2000) 51:634–641.
   PubMed Web of Science ®Google Scholar
• HEINZERLING ML, URBANEK M, FUNK JO et al.: Reduction of tumor burden and stablization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphomas. Cancer (2000) 89: 1835-1844.
   Google Scholar
• •Large multi-centre series of CBCL patients treated with rituximab.
   Google Scholar
• SABROE RA, CHILD FJ, WOOLFORD AJ, SPITTLE MF, RUSSELL JONES R: Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br I Dermatol (2000) 143:157–161.
   PubMed Web of Science ®Google Scholar
• HEINZERLING L, DUMMER R, KEMPF W, HESS-SCHMID M, BURG G: Intralesional therapy with anti-CD20-antibody in primary cutaneous B-cell lymphoma. Arch. Derm. (2000) 136:374–378.
   PubMed Web of Science ®Google Scholar
• DUMMER R, HAEFFNER A, ZEPTER K, WOOD G: t(14;18) translocation and BCL-2 expression in cutaneous B-cell lymphomas and benign B-cell hyperplasias. Melanoma Res. (1993) 3:16.
   Google Scholar
• WILLEMZE R, KERL H, STERRY W et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood (1997) 90:354–371.
   PubMed Web of Science ®Google Scholar
• ••The dermatology-based classification ofCLs.
   Google Scholar
• KUTTING B, BONSMANN G, METZE D, LUGER TA, CERRONI L: Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J. Am. Acad. Dermatol (1997) 36:311–314.
   PubMed Web of Science ®Google Scholar